logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Angioedemas Hereditary

    FiltersReset Filters
    6 results

    • firazyr

      (icatibant acetate)
      Takeda Pharmaceuticals America, Inc.
      Usage: FIRAZYR® (icatibant) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.

    • icatibant

      (Icatibant)
      Alembic Pharmaceuticals Inc.
      Usage: Icatibant injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 years and older.

    • kalbitor

      (Ecallantide)
      Takeda Pharmaceuticals America, Inc.
      Usage: KALBITOR (ecallantide) is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged 12 and older.

    • orladeyo

      (Berotralstat hydrochloride)
      BioCryst Pharmaceuticals Inc.
      Usage: ORLADEYO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 12 and older. It is not approved for treating acute HAE attacks. Recommended dosage is limited to 150 mg once daily to avoid risks such as QT prolongation.

    • sajazir

      (ICATIBANT)
      Cycle Pharmaceuticals Ltd-Uk
      Usage: SAJAZIR (icatibant) injection is indicated for treating acute attacks of hereditary angioedema (HAE) in adults aged 18 and older.

    • takhzyro

      (lanadelumab-flyo)
      Takeda Pharmaceuticals America, Inc.
      Usage: TAKHZYRO® is indicated for the prophylaxis of hereditary angioedema (HAE) attacks in adults and pediatric patients aged 2 years and older.